These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35854372)

  • 1. The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.
    Hein TR; Peterson L; Bartikoski BJ; Portes J; Espírito Santo RC; Xavier RM
    Arthritis Res Ther; 2022 Jul; 24(1):171. PubMed ID: 35854372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
    Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
    Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study.
    Tada M; Matsumoto Y; Koike T; Mamoto K; Nakamura T; Anno S; Iida T; Goto H; Hidaka N
    Int J Rheum Dis; 2024 Oct; 27(10):e15371. PubMed ID: 39381837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on "The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis".
    Minamino H; Torii M; Katsushima M; Fujita Y; Hashimoto M
    Arthritis Res Ther; 2022 Nov; 24(1):245. PubMed ID: 36316781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
    Graudal N; Hubeck-Graudal T; Tarp S; Christensen R; Jürgens G
    PLoS One; 2014; 9(9):e106408. PubMed ID: 25244021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Sarcopenia and its Association with Antirheumatic Drugs in Middle-Aged and Older Adults with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Dao T; Kirk B; Phu S; Vogrin S; Duque G
    Calcif Tissue Int; 2021 Nov; 109(5):475-489. PubMed ID: 34132852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis.
    Hasegawa E; Ito S; Kurosawa Y; Kobayashi D; Otani H; Abe A; Nakazono K; Murasawa A; Narita I; Ishikawa H
    Intern Med; 2023; 62(3):373-379. PubMed ID: 36725065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of anti-rheumatic agents on the periodontal condition of patients with rheumatoid arthritis and periodontitis: A systematic review and meta-analysis.
    Zhang J; Xu C; Gao L; Zhang D; Li C; Liu J
    J Periodontal Res; 2021 Dec; 56(6):1099-1115. PubMed ID: 34514591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis.
    Zhang Q; McDermott GC; Juge PA; Chang SH; Vanni KM; Qian G; Bade KJ; Mueller KT; Kowalski EN; Saavedra AA; Sparks JA
    Semin Arthritis Rheum; 2024 Oct; 69():152561. PubMed ID: 39413452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
    Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
    Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Ovarian Reserve by Serum Anti-Müllerian Hormone in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.
    Zhang XH; Zhang YA; Chen X; Qiao PY; Zhang LY
    Int Arch Allergy Immunol; 2022; 183(4):462-469. PubMed ID: 34929705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Syngle A; Kaur S; Verma I; Syngle T; Syngle V
    Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review.
    Calvo Alén J; Pérez T; Romero Yuste S; Ferraz-Amaro I; Alegre Sancho JJ; Pinto Tasende JA; Maceiras Pan F; Quevedo JC; Hernández-Hernández MV; Hidalgo Calleja C; San Martín Álvarez A; Sánchez MIT; Sanmartí R
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):324-332. PubMed ID: 30241955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Singh JA; Cameron C; Noorbaloochi S; Cullis T; Tucker M; Christensen R; Ghogomu ET; Coyle D; Clifford T; Tugwell P; Wells GA
    Lancet; 2015 Jul; 386(9990):258-65. PubMed ID: 25975452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.
    Steiman AJ; Pope JE; Thiessen-Philbrook H; Li L; Barnabe C; Kalache F; Kung T; Bessette L; Flanagan C; Haraoui B; Hochman J; Leclercq S; Mosher D; Thorne C; Bykerk V
    Rheumatol Int; 2013 May; 33(5):1105-20. PubMed ID: 23292213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of biological disease-modifying antirheumatic drugs on body composition in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    de Souza MPGUES; Guimarães NS; de Resende Guimarães MFB; de Souza VA; Kakehasi AM
    Adv Rheumatol; 2022 May; 62(1):16. PubMed ID: 35606888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
    Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
    Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott IC; Kingsley GH; Scott DL
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.